Lifileucel

Approval Year

Substance Class	Structurally Diverse Created by `admin` on `Wed Apr 02 00:38:06 GMT 2025` Edited by `admin` on `Wed Apr 02 00:38:06 GMT 2025`
Source Materials Class	ORGANISM
Source Materials Type	AUTOLOGOUS HUMAN
Source Materials State	LIVE
Source Materials Parent	`G0T704E6Z3` HOMO SAPIENS WHOLE
Part Location	metastatic melanoma
Part	tumor
Fraction Material Type	cells
Fraction Name	tumor-infiltrating lymphocytes (til)
Record UNII	R0835E18NH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LN-145

Preferred Name

English

Lifileucel

Official Name

English

LIFILEUCEL [USAN]

Common Name

English

TUMOR INFILTRATING LYMPHOCYTES, AUTOLOGOUS (FROM MELANOMA TUMORS)

Common Name

English

AMTAGVI

Brand Name

English

LN 145 [WHO-DD]

Common Name

English

Tumor-infiltrating lymphocytes (TIL). The process for manufacturing lifileucel begins at the clinical site with the excision of tumors of ? 1 cm from metastatic sites, including lymph nodes. Tumor tissue is placed in media and shipped by overnight courie

Common Name

English

lifileucel [INN]

Common Name

English

Autologous tumor-infiltrating lymphocytes (TIL) derived from the patient's own tumor.

Common Name

English

Human culture expanded activated autologous T cells for cell-based immunotherapy. The cell substance is a heterogeneous mixture consisting of CD4+ and CD8+ tumor-infiltrating lymphocytes (TIL), derived from isolated tumor biopsy of patients with melanoma

Common Name

English

LN-144

Code

English

Lifileucel [WHO-DD]

Common Name

English

An autologous CD4+ and CD8+ tumor infiltrating lymphocyte, derived from isolated metastatic melanoma cultured in the presence of feeder cells (irradiated allogeneic mononuclear cells from healthy donors), and human recombinant interleukin 2/Muromonab-CD3

Common Name

English

Code System Code Type Description

USAN

MN-69